Helix BioPharma Corp. (HBPCF)

Helix BioPharma Income Statement

Financials in millions CAD. Fiscal year is August - July.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Selling, General & Admin	1.84	3.26	1.05	1.5	3.25
Research & Development	3.56	5.98	5.28	4.54	5.88
Operating Expenses	5.4	9.24	6.33	6.04	9.13
Operating Income	-5.4	-9.24	-6.33	-6.04	-9.13
Interest Expense	-0.01	-0.01	-0.01	-0.02	-0.02
Interest & Investment Income	0.02	0.03	0.05	0	-
Currency Exchange Gain (Loss)	-0.14	-0.05	-0	-0.01	0.05
Other Non Operating Income (Expenses)	0.31	-	-	0	-0.34
EBT Excluding Unusual Items	-5.22	-9.26	-6.3	-6.06	-9.43
Gain (Loss) on Sale of Assets	0.02	-	0.01	-	-
Other Unusual Items	-	-	-	-0.5	-0.14
Pretax Income	-5.21	-9.26	-6.29	-6.56	-9.57
Earnings From Continuing Operations	-5.21	-9.26	-6.29	-6.56	-9.57
Earnings From Discontinued Operations	-	-	-	-	1.54
Net Income to Company	-5.21	-9.26	-6.29	-6.56	-8.04
Net Income	-5.21	-9.26	-6.29	-6.56	-8.04
Net Income to Common	-5.21	-9.26	-6.29	-6.56	-8.04
Shares Outstanding (Basic)	56	44	39	30	28
Shares Outstanding (Diluted)	56	44	39	30	28
Shares Change (YoY)	25.29%	15.11%	29.26%	8.41%	7.97%
EPS (Basic)	-0.09	-0.21	-0.16	-0.22	-0.29
EPS (Diluted)	-0.09	-0.21	-0.16	-0.22	-0.29
Free Cash Flow	-3.83	-5.23	-5.54	-6.51	-9.3
Free Cash Flow Per Share	-0.07	-0.12	-0.14	-0.22	-0.34
EBITDA	-5.39	-9.23	-6.31	-6.03	-9.07
D&A For EBITDA	0.01	0.01	0.01	0.01	0.06
EBIT	-5.4	-9.24	-6.33	-6.04	-9.13

Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.